A pilot study of buspirone in the treatment of social phobia

Seventeen patients who met DSM-III-R criteria for social phobia were seen in an eight week open trial of buspirone. Eleven subjects completed the study, having taken an average of 48 mg per day of medication by the end of week 8. Rating scales of generalized anxiety, social anxiety, depression, and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of anxiety disorders 1991, Vol.5 (1), p.87-98
Main Authors: Munjack, Dennis J., Bruns, Jerry, Baltazar, Patricia L., Brown, Richard, Leonard, Michelle, Nagy, Robert, Koek, Ralph, Crocker, Benjamin, Schafer, Stuart
Format: Article
Language:English
Subjects:
Biological and medical sciences
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Seventeen patients who met DSM-III-R criteria for social phobia were seen in an eight week open trial of buspirone. Eleven subjects completed the study, having taken an average of 48 mg per day of medication by the end of week 8. Rating scales of generalized anxiety, social anxiety, depression, and disability were administered. Preliminary findings indicated that 1) buspirone is an effective anxiolytic for anxiety in general, and 2) generalized social phobia symptoms partially responded to buspirone, although few patients responded dramatically. The limitations of this study and some problems with the assessment instruments are discussed. Recommendations for future studies are offered.
ISSN:0887-6185
1873-7897
DOI:10.1016/0887-6185(91)90019-P